EXECUTIVE INTERVIEWS

• Will Pyxis Oncology Be Pfizer’s Fourth Billion-Dollar Spinout?

  After working at Pfizer and being instrumental in the SpringWorks spinout, Lara Sullivan, M.D., is no stranger to building pharma companies. But getting to where she is today as CEO of Pyxis Therapeutics hasn’t come without its challenges.

• Reflection And Projection 2.0 — 15 CEOs Map Biopharma’s Present And Future

  In this outlook article with 15 biopharma CEOs, they talk about everything from trends to watch, to disruptive innovations to the effects and future of remote work on the industry.

• What’s The Biopharma Financial View For 2022?

  Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

• What’s The Outlook From Life Science Operations For 2022 — And Beyond?

  With the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems leaders in biopharma manufacturing have never faced a greater challenge. Here’s what 12 of those execs have to say as they look to 2022 and beyond.

• Can the FDA & CDC Recover from Recent Politics?

  Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

• Formulation Alternatives: Looking Beyond Parenteral Biologics

  2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.

• These Professionals Are Creating Our Outsourcing Future

  While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.

• Is Janssen’s Pathway Approach The Future Of Drug Development

  Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.

• What To Expect From Cell Therapy And Gene Therapy In 2022 And Beyond

  From innovations in clinical development and manufacturing to the evaluation of investigational cell and gene therapies (CGTs), subject matter experts from Cellectis and Immatics share a brief look back on 2021 and a detailed glimpse into the near future of gene therapy and cell therapy respectively.

• Long Hauler In The Antibiotics Space

  For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

• Jaguar Health’s Lisa Conte — An Entrepreneurial Ascent Like No Other

  Lisa Conte’s idea was to do more efficient drug discovery and development by leveraging the knowledge of “traditional healers.” However, like most entrepreneurial climbs, it would prove arduous, with plenty of slips, trips, and spills along the way.

• Going Precommercial — From The Commercial World

  Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

• $4 Billion In 4 Years: The Story Of SpringWorks Therapeutics

  Saqib Islam was one of the five founding members of SpringWorks Therapeutics, which was spun out of Pfizer in 2017. An atypical startup, the company launched with the rights to four clinical-stage experimental therapies and grew quickly in the next few years.

• Becoming A Clinical-Stage Biotech

  A Q&A with Laura Indolfi, CEO and cofounder of PanTher Therapeutics, which recently closed its Series A funding round and is preparing for its first clinical trials.